(News from 2021 BTW):
One Arena Pharmaceuticals product on the market (”Belviq”, weight loss)...ones in development are:
“The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company’s pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension (lungs). As of September 2014, potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmonary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin.
In 2018, Arena’s etrasimod, a drug directed at treating ulcerative colitis (and a competitor with ozanimod from Celgene), passed phase II clinical trials successfully and moved on to phase III.”
https://en.wikipedia.org/wiki/Arena_Pharmaceuticals
Also more here:
https://www.cnbc.com/2021/12/13/pfizer-to-acquire-arena-pharmaceuticals-in-6point7-billion-deal-.html
(One mention of a cardiology drug in far-term development)...main near-term focus of development is “Etrasimod” (ulcerative colitis and Crohn’s disease).
I’m sure my pulmonary “doctor” will be pushing the Ralinepag on me.
My pulmonary “doctor” was pushing this (Ofev/Nintedanib) on me before. Who in his right mind would take this! He said in a later yearly appointment that he was going to make me take this, lol.
https://pro.boehringer-ingelheim.com/us/products/ofev/ipf/lung-function